- Home
- BJRI vs SNDX Comparison
BJRI vs SNDX Comparison
Compare BJRI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJRI
- SNDX
- Stock Information
- Founded
- BJRI 1978
- SNDX 2005
- Country
- BJRI United States
- SNDX United States
- Employees
- BJRI N/A
- SNDX N/A
- Industry
- BJRI Restaurants
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BJRI Consumer Discretionary
- SNDX Health Care
- Exchange
- BJRI Nasdaq
- SNDX Nasdaq
- Market Cap
- BJRI 978.8M
- SNDX 1.1B
- IPO Year
- BJRI 1996
- SNDX 2016
- Fundamental
- Price
- BJRI $45.99
- SNDX $9.48
- Analyst Decision
- BJRI Hold
- SNDX Strong Buy
- Analyst Count
- BJRI 5
- SNDX 11
- Target Price
- BJRI $38.25
- SNDX $35.91
- AVG Volume (30 Days)
- BJRI 475.5K
- SNDX 1.9M
- Earning Date
- BJRI 07-24-2025
- SNDX 07-31-2025
- Dividend Yield
- BJRI N/A
- SNDX N/A
- EPS Growth
- BJRI N/A
- SNDX N/A
- EPS
- BJRI 0.95
- SNDX N/A
- Revenue
- BJRI $1,367,941,000.00
- SNDX $43,722,000.00
- Revenue This Year
- BJRI $5.50
- SNDX $426.77
- Revenue Next Year
- BJRI $3.00
- SNDX $98.31
- P/E Ratio
- BJRI $48.29
- SNDX N/A
- Revenue Growth
- BJRI 2.91
- SNDX N/A
- 52 Week Low
- BJRI $27.61
- SNDX $8.58
- 52 Week High
- BJRI $46.26
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- BJRI 66.34
- SNDX 36.85
- Support Level
- BJRI $43.00
- SNDX $11.00
- Resistance Level
- BJRI $46.17
- SNDX $11.83
- Average True Range (ATR)
- BJRI 1.30
- SNDX 0.58
- MACD
- BJRI -0.14
- SNDX -0.11
- Stochastic Oscillator
- BJRI 93.16
- SNDX 10.31
About BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.